104 related articles for article (PubMed ID: 26389834)
1. Urinary-derived human chorionic gonadotropin to induce tolerance and promote healing in steroid-refractory GvHD.
Holtan SG; Panoskaltsis-Mortari A
Bone Marrow Transplant; 2016 Jan; 51(1):142-3. PubMed ID: 26389834
[No Abstract] [Full Text] [Related]
2. Human chorionic gonadotropin and indolamine 2,3-dioxygenase in patients with GVHD.
Elmaagacli AH; Ditschkowski M; Steckel NK; Gromke T; Ottinger H; Hillen U; Baba HA; Trenschel R; Beelen DW; Koldehoff M
Bone Marrow Transplant; 2014 Jun; 49(6):800-5. PubMed ID: 24686986
[TBL] [Abstract][Full Text] [Related]
3. Increased plasma indoleamine 2,3-dioxygenase activity and interferon-γ levels correlate with the severity of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Xu J; Wei J; Zhu X; Zhang X; Guan J; Wang J; Yin J; Xiao Y; Zhang Y
Biol Blood Marrow Transplant; 2013 Feb; 19(2):196-201. PubMed ID: 23089565
[TBL] [Abstract][Full Text] [Related]
4. Potential immunosuppressive function of plasma indoleamine 2,3-dioxygenase in patients with aGVHD after allo-HSCT.
Zhao XS; Liu KY; Liu DH; Xu LP; Chen H; Huang XJ
Clin Transplant; 2011; 25(3):E304-11. PubMed ID: 21355883
[TBL] [Abstract][Full Text] [Related]
5. miR-153-3p, a new bio-target, is involved in the pathogenesis of acute graft-versus-host disease via inhibition of indoleamine- 2,3-dioxygenase.
Zhao XS; Wang YN; Lv M; Kong Y; Luo HX; Ye XY; Wu Q; Zhao TF; Hu YH; Zhang HY; Huo MR; Wan J; Huang XJ
Oncotarget; 2016 Jul; 7(30):48321-48334. PubMed ID: 27340781
[TBL] [Abstract][Full Text] [Related]
6. Treatment options in steroid-refractory acute graft-versus-host disease following hematopoietic stem cell transplantation.
Kim SS
Ann Pharmacother; 2007 Sep; 41(9):1436-44. PubMed ID: 17684033
[TBL] [Abstract][Full Text] [Related]
7. Basiliximab for the treatment of steroid-refractory acute graft-versus-host disease after unmanipulated HLA-mismatched/haploidentical hematopoietic stem cell transplantation.
Wang JZ; Liu KY; Xu LP; Liu DH; Han W; Chen H; Chen YH; Zhang XH; Zhao T; Wang Y; Huang XJ
Transplant Proc; 2011 Jun; 43(5):1928-33. PubMed ID: 21693302
[TBL] [Abstract][Full Text] [Related]
8. Outcome of gastrointestinal graft-versus-host disease according to the treatment response.
Tamaki M; Nakasone H; Misaki Y; Yoshimura K; Gomyo A; Hayakawa J; Kusuda M; Akahoshi Y; Ishihara Y; Kawamura K; Tanihara A; Sato M; Terasako-Saito K; Kameda K; Wada H; Kikuchi M; Kimura SI; Kako S; Kanda Y
Ann Hematol; 2018 Oct; 97(10):1951-1960. PubMed ID: 29860563
[TBL] [Abstract][Full Text] [Related]
9. A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation.
Khandelwal P; Emoto C; Fukuda T; Vinks AA; Neumeier L; Dandoy CE; El-Bietar J; Chandra S; Davies SM; Bleesing JJ; Jordan MB; Mehta PA; Jodele S; Grimley MS; Kumar A; Myers KC; Marsh RA
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2220-2225. PubMed ID: 27664325
[TBL] [Abstract][Full Text] [Related]
10. Low bone mineral density in adolescents with leukemia after hematopoietic stem cell transplantation: prolonged steroid therapy for GvHD and endocrinopathy after hematopoietic stem cell transplantation might be major concerns?
Cho WK; Ahn MB; Lee JW; Chung NG; Jung MH; Cho B; Suh BK
Bone Marrow Transplant; 2017 Jan; 52(1):144-146. PubMed ID: 27479687
[No Abstract] [Full Text] [Related]
11. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Busca A; Locatelli F; Marmont F; Ceretto C; Falda M
Am J Hematol; 2007 Jan; 82(1):45-52. PubMed ID: 16937391
[TBL] [Abstract][Full Text] [Related]
12. Mycophenolate mofetil is effective only for involved skin in the treatment for steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Hattori K; Doki N; Kurosawa S; Hino Y; Yamamoto K; Sakaguchi M; Harada K; Ikegawa S; Shingai N; Senoo Y; Igarashi A; Najima Y; Kobayashi T; Kakihana K; Sakamaki H; Ohashi K
Ann Hematol; 2017 Feb; 96(2):319-321. PubMed ID: 27766393
[No Abstract] [Full Text] [Related]
13. Immunological effects in patients with steroid-refractory graft-versus-host disease following treatment with basiliximab, a CD25 monoclonal antibody.
Chakupurakal G; García-Márquez MA; Shimabukuro-Vornhagen A; Theurich S; Holtick U; Hallek M; Scheid C; von Bergwelt-Baildon M
Eur J Haematol; 2016 Aug; 97(2):121-7. PubMed ID: 26492560
[TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up of patients treated with daclizumab for steroid-refractory acute graft-vs-host disease.
Perales MA; Ishill N; Lomazow WA; Weinstock DM; Papadopoulos EB; Dastigir H; Chiu M; Boulad F; Castro-Malaspina HR; Heller G; Jakubowski AA; O'Reilly RJ; Small TN; Young JW; Kernan NA
Bone Marrow Transplant; 2007 Sep; 40(5):481-6. PubMed ID: 17618322
[TBL] [Abstract][Full Text] [Related]
15. Response of Steroid-Refractory Acute GVHD to α1-Antitrypsin.
Marcondes AM; Hockenbery D; Lesnikova M; Dinarello CA; Woolfrey A; Gernsheimer T; Loghman-Adham M; Gelmont D; Storer B; Hansen JA; Deeg HJ
Biol Blood Marrow Transplant; 2016 Sep; 22(9):1596-1601. PubMed ID: 27223109
[TBL] [Abstract][Full Text] [Related]
16. [Anti-CD(25) monoclonal antibody as a salvage therapy for steroid-refractory acute graft-versus-host disease in 80 patients receiving allogeneic hematopoietic stem cell transplantation].
Tao T; Xue SL; Chen F; Xu Y; Ma X; Miao M; Tang XW; Wu DP
Zhonghua Nei Ke Za Zhi; 2018 May; 57(5):324-329. PubMed ID: 29747286
[No Abstract] [Full Text] [Related]
17. Allogeneic stem cell transplantation as treatment for heavily treated, refractory acute graft-versus-host disease after HLA-mismatched stem cell transplantation.
Ikegame K; Yoshihara S; Taniguchi Y; Kaida K; Inoue T; Okada M; Taniguchi K; Hasei H; Tamaki H; Fujioka T; Kato R; Soma T; Ogawa H
Exp Hematol; 2011 Aug; 39(8):880-90. PubMed ID: 21689724
[TBL] [Abstract][Full Text] [Related]
18. Clinical utility of rituximab in chronic graft-versus-host disease.
Bates JS; Engemann AM; Hammond JM
Ann Pharmacother; 2009 Feb; 43(2):316-21. PubMed ID: 19193571
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment with steroids of upper gastrointestinal acute graft vs. host disease after hematopoietic stem cell transplantation.
Nishi T; Okazaki K; Fujii S; Uchida K; Uose S; Nakase H; Ohana M; Nishihara T; Chiba T
Endoscopy; 2001 Nov; 33(11):985-7. PubMed ID: 11668409
[TBL] [Abstract][Full Text] [Related]
20. Daclizumab as useful treatment in refractory acute GVHD: a paediatric experience.
Miano M; Cuzzubbo D; Terranova P; Giardino S; Lanino E; Morreale G; Castagnola E; Dini G; Faraci M
Bone Marrow Transplant; 2009 Mar; 43(5):423-7. PubMed ID: 18850021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
